Phaseline

Companies › Il-Yang Pharm.

Il-Yang Pharm.: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Neurology, Oncology, Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Radotinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 3Chronic Myeloid Leukemia, Chronic Phase; Parkinson DiseaseApr 2027
Ilaprazole
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Peptic UlcerAug 2027
IY-828026–Phase 1HealhtyMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07433556IY-828026Phase 1HealhtyOtherMar 2027
NCT04691661RadotinibPhase 2Parkinson DiseaseNeurologyApr 2027
NCT03459534RadotinibPhase 3Chronic Myeloid Leukemia, Chronic PhaseOncologyJun 2027
NCT06284876IlaprazolePhase 3Peptic UlcerGastroenterologyAug 2027
NCT03722420RadotinibPhase 3Chronic Myeloid Leukemia, Chronic PhaseOncologyDec 2027

Targets

ATP4A (1) ATP4B (1) ABL1 (1) BCR (1)

Companies with the same targets

Phathom Pharmaceuticals Carnot Laboratories AstraZeneca Ascentage Pharma Group Takeda Incyte Biosciences International Sàrl Enliven Therapeutics Novartis Taiho Pharmaceutical Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Companies built like this

Onconic Therapeutics InventisBio Guangzhou Lupeng Pharmaceutical Company SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany SK Life Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.